Agreements reached under this partnership
Capital and Business Alliance- 1
The parties will collaborate toward the development and commercialization of this product in Japan.
- 2
The Alfresa Holdings Group will provide comprehensive support by leveraging its CRO, manufacturing, distribution and other capabilities across areas including clinical development support, manufacturing and distribution related to this product.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The impact of this transaction on performance for the current fiscal year is expected to be immaterial, but the Company believes it will contribute to enhancing the corporate value of the Group over the medium to long term.
| Item | Details |
|---|---|
| Name of alliance partner | 株式会社ReeNT |
| Alliance partner's business activities | Research and development of regenerative medicine products in the field of otolaryngology |
| Alliance partner's location | Minato-ku, Tokyo |
| Alliance partner's capital | ¥95 million |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | The parties will collaborate toward the development and commercialization of this product in Japan., The Alfresa Holdings Group will provide comprehensive support by leveraging its CRO, manufacturing, distribution and other capabilities across areas including clinical development support, manufacturing and distribution related to this product. |
| Number of shares acquired | 1,000 common shares (representing 16.1% of the total number of shares issued following the investment) |
| Acquisition price | Total amount paid: ¥600 million |
| Shareholding ratio | 3.4% → 16.1% |
| Contract Date | 27 May 2026 |
| Impact on Business Performance | The impact of this transaction on performance for the current fiscal year is expected to be immaterial, but the Company believes it will contribute to enhancing the corporate value of the Group over the medium to long term. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate the implementation of regenerative medicine technologies in society by leveraging the strengths of both companies, and to pursue the commercialization in Japan of the autologous nasal mucosal epithelial cell sheet being developed by 株式会社ReeNT.